Related Experiment Video
Updated: Jul 8, 2026
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
09:34
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
Liposomal cytarabine for leukemic and lymphomatous meningitis: recent developments
Martin Benesch1, Christian Urban
1Medical University of Graz, Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Auenbruggerplatz 30, A-8036 Graz, Austria. martin.benesch@klinikum-graz.at
Expert Opinion on Pharmacotherapy
|January 19, 2008
Summary
Liposomal cytarabine offers improved treatment for CNS leukemia/lymphoma, showing better response rates than free cytarabine. However, potential neurologic side effects require careful administration protocols.
Area of Science:
- Oncology
- Pharmacology
- Neurology
Background:
- Liposomal cytarabine is a sustained-release formulation for intrathecal administration.
- It is increasingly used for central nervous system (CNS) involvement in leukemia/lymphoma.
- Current clinical trials are often retrospective or compassionate use.
Purpose of the Study:
- To evaluate the efficacy and safety of liposomal cytarabine for CNS involvement.
- To compare liposomal cytarabine with standard intrathecal therapy.
Main Methods:
- Review of existing clinical trials, including a randomized Phase III study.
- Analysis of treatment response rates and adverse events.
- Consideration of administration timing relative to systemic chemotherapy.
Main Results:
- One Phase III study demonstrated significantly better response rates with liposomal cytarabine versus free cytarabine in lymphomatous meningitis.
- Concerns exist regarding potential neurotoxicity when administered closely with high-dose systemic chemotherapy.
Conclusions:
- Liposomal cytarabine shows promise for CNS leukemia/lymphoma treatment.
- Prospective trials are needed to confirm superior efficacy.
- Adherence to preventive measures may mitigate associated neurologic side effects.